Discover how BillionToOne's revolutionary blood test technology detects cancer and genetic diseases before they spread. Learn the science behind early detect...
How Blood Tests Can Detect Cancer Early: BillionToOne's Medical Breakthrough
Key Insights
- Revolutionary Detection Technology: BillionToOne uses cell-free DNA analysis from blood samples to detect genetic abnormalities and cancer with unprecedented accuracy, processing over 600,000 tests annually.
- The Needle-in-a-Haystack Problem: Finding one mutated base pair among three billion requires adding synthetic DNA markers to distinguish real signals from amplification noise using advanced machine learning.
- Three-Step Market Strategy: The company strategically launched with prenatal testing, expanded to late-stage cancer detection, and is moving toward early-stage cancer screening—the true "holy grail" of oncology.
- Rapid Commercialization: From PhD students with a half lab bench and $300,000 to a $4 billion public company in just years, demonstrating exceptional execution and product-market fit.
- Impact on Patient Care: The technology has already saved lives, including a metastatic cancer patient who found viable immunotherapy options through blood testing when traditional tumor biopsies showed nothing.
Understanding the Genetic Detection Challenge: Why BillionToOne's Solution Matters
The human genome contains three billion base pairs, and most genetic diseases are caused by just a single base pair difference. This creates an almost impossible detection problem: finding that one mutation among billions of other DNA fragments naturally floating in the bloodstream. Before BillionToOne, detecting these abnormalities required invasive procedures like amniocentesis, which doctors only performed on high-risk pregnancies due to miscarriage risks.
Traditional genetic testing amplifies all DNA in blood samples using a process called PCR, but this indiscriminate amplification introduces massive amounts of noise that can drown out the actual signal you're looking for. The small fragment of fetal DNA or tumor DNA gets lost in a sea of background noise from normal cells. This is why previous companies and researchers couldn't solve this problem—they were trying to find a signal that was being obscured by the very amplification process designed to reveal it.
BillionToOne's breakthrough insight came from combining biology with sophisticated data science. Before any amplification happens, they add precisely known synthetic DNA molecules to the patient sample. Because they know exactly what they added, they can use machine learning to calculate how much distortion the amplification process introduced at different genomic locations. This transforms what seems like an impossible biological problem into an elegant mathematical one: subtract the known noise, and what remains is the true signal. This approach allows them to spot genetic mutations and cancer markers that no other test can reliably detect.
The company's co-founders, Oguzhan and David, met as undergraduates and reconnected years later when Oguzhan called with an exciting idea about starting a company. Both were studying biology-related fields—Oguzhan at Stanford and David at Rice University—and they approached the cell-free DNA problem from first principles. They realized that if they could reduce the noise in blood sample analysis, they could directly detect conditions like sickle cell disease, cystic fibrosis, and thalassemias from maternal blood samples. Since sickle cell and beta thalassemia are among the most common genetic disorders worldwide, they understood they could potentially help millions of patients.
From Startup Struggle to Clinical Reality: How BillionToOne Executed Faster Than Anyone Expected
Most companies take a decade to bring a genetic test to market, but BillionToOne accomplished this in just two years. How? The founders believe it required genuine interdisciplinary thinking—not teams of specialists in separate silos, but scientists who personally understood both the chemistry of how DNA is generated and the data science of how to analyze it. This rare combination allowed them to see solutions that pure chemists or pure data scientists would miss.
The early days were brutally humble. Their first lab space wasn't a dedicated facility—they shared a bench with another startup founder. Chemical suppliers wouldn't even sell to them without proof of a bank account and ability to pay. Raising their first $300,000 took six months of grinding through rejection, securing $10,000 at a time. Despite this resource constraint, they developed their test and received regulatory approval.
Then came the harsh reality of launching a medical product: two months after their June launch, they had exactly one doctor using the test, ordering maybe one or two samples per week. This could have been devastating, but instead of giving up, the founders recognized a critical insight. They could convince individual patients and physicians one-on-one, but they weren't reaching enough of them. The solution? They hired five new sales representatives in three weeks, trained them over the weekend, and deployed them to the field on Monday morning.
More importantly, they shifted their marketing strategy. Rather than trying to convince doctors directly, they educated patients about the test and empowered patients to ask their doctors about it. Their inside sales team spent 30-45 minutes on the phone with each prospective patient, explaining how the test worked and why it differed from alternatives. This patient-focused approach worked—they achieved a one-in-five conversion rate of interested patients actually getting tested. Once they demonstrated genuine traction, experienced salespeople wanted to join the company. With momentum established and revenue flowing, they could finally invest in building the state-of-the-art laboratory they operate today.
The sample processing workflow reveals how much sophistication lies behind the scenes. When blood samples arrive at their lab, they're immediately logged into a laboratory information management system to preserve sample identity through a 5-7 day analysis process. This accessioning step initially became a bottleneck when processing thousands of samples daily. Rather than hiring more staff, BillionToOne invested in computer vision and artificial intelligence, completely redesigning the workflow in a project called "Accessioning in 60 Seconds." Now, machines with optical sensors automatically identify plasma layers and remove only the cell-free DNA fraction needed for analysis.
In their proprietary reagent manufacturing lab, they create quantitative counting templates—the synthetic DNA markers that serve as their secret weapon. These markers are added to every sample before amplification, allowing them to measure and remove bias from the final results. The company believes they can expand this facility to process close to 2 million tests annually, which would represent screening roughly one in three babies born in America.
The sequencing process itself is ingeniously efficient. Rather than running each sample separately, they combine plasma from thousands of samples into a single droplet for sequencing. Before combination, each sample is marked with a unique DNA barcode. When they analyze the resulting data, every sequence tagged with a specific barcode belongs to that patient. It seems like "black magic," as one observer noted, but it's simply clever application of molecular biology and computational biology.
At the end of the processing line, laboratory directors, genetic counselors, and sometimes 20 scientists collaborate on complex cases to ensure accurate reporting. However, the vast majority of samples follow the "happy path"—they produce expected results and are automatically analyzed and reported. This combination of automation for straightforward cases and expert human review for complex cases ensures both efficiency and accuracy.
Expanding Beyond Prenatal Testing: BillionToOne's Assault on Cancer Detection
From the company's founding, Oguzhan and David envisioned a three-step plan that mirrored Tesla's famous roadmap: start with a focused, achievable goal; use the resources generated to tackle progressively harder problems; and eventually address the largest market opportunity. Step one was prenatal genetic testing. Step two is late-stage cancer detection. Step three is the holy grail: early-stage cancer screening.
The founders realized that cell-free fetal DNA and cell-free tumor DNA present essentially identical detection problems. The same technology that finds one mutated base pair among billions works for spotting cancer DNA in the bloodstream. By choosing the right initial market—prenatal testing—they generated revenue and resources that made expansion into oncology feasible. Had they started with cancer screening, they would have needed to raise over a billion dollars before generating a single dollar of revenue, an impossible feat for first-time founders.
In 2023, they launched their first cancer test commercially, proving their ability to execute in two completely different markets simultaneously. This is a remarkable achievement that demonstrates the universality of their core technology. The Northstar Select test can identify specific tumor characteristics, including microsatellite instability that qualifies patients for immunotherapy.
One patient case study illustrates the profound impact. A person in their 40s with metastatic colorectal cancer had exhausted conventional treatment options and was preparing to enter hospice care. Their tumor had spread to multiple locations, making targeted treatment options appear exhausted. However, BillionToOne's blood test identified microsatellite instability in the circulating tumor DNA—a finding their conventional tumor biopsy had missed, likely because the biopsy happened to sample a location without that specific alteration.
Based on this blood test result, the patient became eligible for immunotherapy despite what their tumor biopsy suggested. The treatment worked remarkably well—as some doctors describe it, "the cancer melted away." The patient continues to do well years later, and the physician is now sending blood tests from essentially all cancer patients, impressed by results the company achieved where traditional testing failed.
The company is currently on step two of their roadmap: using their technology for patients with late-stage cancer to guide treatment decisions and monitor disease progression. Step three involves detecting minimal residual disease—microscopic remnants of tumor DNA remaining after surgery in stage 1-2 cancer patients. Approximately 20% of patients who undergo curative surgery for early-stage cancer develop recurrence, often from undetectable microscopic disease. BillionToOne's technology can detect tumor DNA at levels far below what imaging can identify, potentially enabling earlier intervention before cancer becomes advanced again.
Step four—true early-stage cancer screening in healthy individuals—represents the ultimate goal. If the company can reliably detect microscopic tumor DNA in asymptomatic people through annual blood screening, it solves the same technical problem as detecting minimal residual disease, just in a different population. This would represent one of medicine's greatest achievements: identifying cancers before they cause symptoms or spread, when they're most treatable.
Building an Interdisciplinary Team to Solve the Unsolvable
As BillionToOne has grown to a $4 billion public company, the founders remain intensely focused on hiring philosophy. They don't build interdisciplinary teams—they hire interdisciplinary people. A scientist who can move between molecular biology, chemistry, and data science iteration creates faster progress than specialists working in separate departments. The research structure reflects this philosophy: principal investigators who are genuinely interdisciplinary lead small teams of two or three research associates who report directly to the founders.
This flat structure creates what the founders describe as "many startups within the larger company." Each product team owns end-to-end development, from conception through commercialization. Because iteration cycles are fast and bureaucracy is minimal—they can directly unblock scientists when needed—small teams accomplish what would take much larger organizations. The founders spend significant time each week with their R&D scientists, maintaining the startup mentality that made the company successful.
Remarkably, even though most BillionToOne employees could retire following the company's public offering, they continue working. This retention speaks to the genuine challenge and impact of the work. Changing healthcare is difficult. Growing profitably while also improving healthcare is even more difficult. The company makes this clear to prospective employees: joining BillionToOne means tackling one of the most challenging problems you'll ever face professionally.
Yet employees choose to stay because they know that solving it—potentially making "the biggest dent in cancer that has happened in the last hundred years"—matters more than early retirement. As the founders say, "pressure is a privilege," and the people drawn to this company want to take on that pressure. They want to contribute to transforming cancer detection and saving millions of lives through the application of brilliant science and rigorous execution.
Conclusion
BillionToOne's journey from two PhD students with a half lab bench and $300,000 to a company processing over 600,000 tests annually demonstrates what's possible when brilliant people solve the right problems in the right order. Their cell-free DNA technology, powered by synthetic DNA markers and machine learning, eliminates the needle-in-a-haystack problem that prevented earlier breakthroughs in genetic and cancer detection.
By starting with prenatal testing and systematically moving toward early-stage cancer screening, they've charted a path to genuinely transforming healthcare. They're not just improving diagnosis—they're fundamentally changing when diseases get detected, when treatment starts, and ultimately, how many lives get saved. If they achieve their vision of screening everyone once yearly for early-stage cancer, they'll have solved one of medicine's great unsolved problems. For patients, clinicians, and healthcare systems worldwide, that would represent an achievement worthy of all the pressure and privilege involved in building it.
Original source: This Startup Wants To Catch Cancer Before It Spreads
powered by osmu.app